ReTune Study
/ hīpō • Gōna • dizəm /
Commonly referred to “Low Testosterone” or “Testosterone Deficiency”, this disease has a profound impact on the lives of men of all ages who present symptoms such erectile dysfunction, depression, fatigue, anemia, increased body fat and more. Male hypogonadism affects 15 million in the US alone.
At Marius, we continue to research and investigate the vital role testosterone plays in all of these functions and more in order to make sure those afflicted can live their best possible lives.
The ReTUne Study is our pivotal Phase 3 study with a main study and extension study measuring the efficacy and safety of our proprietary Oral Testosterone for primary and secondary hypogonadism in males aged 18-65. From a design perspective, one of the most comprehensive trials to date, we tested 295 patients across 6 and 12 month studies and some patients had a total of 18 months of exposure to the drug. We have tested for exploratory endpoints including Patient Reported Outcomes and other important biomarkers. This study was successfully completed in 2019.
The proposed indications for Kyzatrex demonstrated through the study are:
- Primary hypogonadism (congenital or acquired): testicular failure due to cryptorchidism, bilateral torsion, orchitis, vanishing testis syndrome, orchiectomy, Klinefelter syndrome, chemotherapy, or toxic damage from alcohol or heavy metals. These men usually have low serum testosterone concentrations and gonadotropins (follicle-stimulating hormone [FSH], luteinizing hormone [LH]) above the normal range.
- Hypogonadotropic hypogonadism (congenital or acquired): gonadotropin or luteinizing hormone-releasing hormone (LHRH) deficiency or pituitary-hypothalamic injury from tumors, trauma, or radiation. These men have low testosterone serum concentrations but have gonadotropins in the normal or low range.
Comorbidity Rate with Low-T
Formulation Innovation
Lymphatic Absorption
Important Industry Papers
"Nine resolutions were debated amongst an international expert consensus conference, with unanimous approval (including) 1. TD (Testosterone Deficiency) is a well-established, clinically significant medical condition that negatively affects male sexuality, reproduction, general health and quality of life 2. the evidence does not support increased risks of cardiovascular events with T therapy, 3. The evidence supports a major research initiative to explore the benefits of T therapy for cardiometobolic disease including diabetes."
"More than 100 other studies have shown no increased CV risk, or even reduced risk, among men with higher endogenous testosterone concentrations or who received testosterone therapy. High-level evidence demonstrates an inverse relationship for serum testosterone and mortality, incident coronary artery disease, severity of coronary artery disease, atherosclerosis, and carotid intima-media thickness."